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Abstract
L-Glutamine (Gln) functions physiologically to balance tissue requirements of carbon and 
nitrogen. It has been proposed that in cancer cells undergoing aerobic glycolysis, accelerated 
anabolism is sustained by Gln-derived carbons, which replenish the tricarboxylic acid (TCA) cycle 
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(anaplerosis). However, it is shown here that in glioblastoma (GBM) cells, almost half of the Gln-
derived glutamate (Glu) is secreted and does not enter the TCA cycle and, that inhibiting 
glutaminolysis does not affect proliferation. Moreover, Gln-starved cells are not rescued by TCA 
cycle replenishment. Instead, the conversion of Glu to Gln by Glutamine Synthetase (GS) 
(cataplerosis) confers Gln prototrophy, and fuels de novo purine biosynthesis. In both orthotopic 
GBM models and in patients, 13C-glucose tracing showed that GS produces Gln from TCA cycle-
derived carbons. Finally, while it is contributed only marginally by the circulation, the Gln 
required for the growth of GBM tumours is either autonomously synthesized by GS-positive 
glioma cells, or supplied by astrocytes.
INTRODUCTION
Gln and Glu constitute a metabolic hub in cellular physiology. An increased demand for Gln 
by transformed cells has been recognized by biochemists for almost a century and, it has 
been linked to its role as an abundant circulating respiratory fuel1. Notably, Gln carbons can 
support anabolism through entering the TCA cycle via glutaminolysis. Only specific tumour 
types display Gln-dependency2-9 whereby its genetic and metabolic basis remains debatable. 
In certain cancer models, the inhibition of glutaminase (GLS), which deaminates Gln to Glu, 
reduces proliferation and tumorigenicity10. Conversely, GLS2 can be induced by the tumour 
suppressor p5311, and in human hepatocellular carcinoma, ｴ-catenin increases the 
expression of GS, which catalyses the reversed GLS reaction12. Originally, tuning of the 
Gln-Glu cycle was observed in the central nervous system13 where Glu is the most abundant 
neurotransmitter14. Unlike astrocytes, glioma cells can release neuro-exitotoxic amounts of 
Glu, potentially promoting tumorigenesis15. Gln-addiction has been proposed as a mark of 
GBM, the most aggressive glioma4. Here, we dissected the differential metabolic roles of 
Gln-derived carbon and nitrogen atoms in sustaining anabolism and growth in six human 
established GBM cell lines, in primary GBM stem-like cells, and in normal astrocytes. 
Additionally, Gln-related metabolism was investigated in both primary orthotopic murine 
xenografts and in GBM patients, leading to the identification of a GBM-astrocyte metabolic 
crosstalk.
RESULTS
Gln starvation reduces GBM cell proliferation unsystematically
To explore their growth response to different nutrient supplies, GBM cells were incubated 
either in DMEM containing supra-physiological concentrations of glucose and lacking some 
of the non-essential amino acids, or in a newly-formulated SMEM, containing nutrient 
concentrations comparable to human serum (Supplementary Table 1). Both media were 
supplemented with various concentrations of Gln (Fig. 1a). In serum-like medium, all cell 
lines grew comparably to or faster than cells cultured in DMEM. In both media, the minimal 
Gln concentration required for maximal growth was below 0.65 mM, hereafter used as the 
control concentration. In the absence of Gln, cells grew faster in SMEM, demonstrating that 
medium formulation affects the response to Gln deprivation. Gln starvation hindered 
proliferation to different extents (Fig. 1b and Supplementary Fig. 1a) without inducing cell 
death, contrary to previous reports3,4, and to their response to glucose withdrawal (Fig. 1c). 
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DNA flow-cytometry analysis showed that Gln starvation did not cause cell cycle arrest at 
any particular phase (Fig. 1d and Supplementary Fig. 1b). Overall, Gln withdrawal resulted 
in cell line-specific growth inhibition, ranging from 20% for U251 and SF188, to 80% for 
LN18 cells (Fig. 1e), independently of the initial proliferation rate (Fig. 1f).
Gln-based anaplerosis is not essential for the proliferation of GBM cell lines
To investigate cellular metabolic alterations upon Gln starvation, the exchange rate of 
metabolites between cells and medium was analysed by HPLC-MS. Gln was the second 
most consumed nutrient by all cell lines (Supplementary Fig. 2 and Supplementary Table 2). 
However, no clear relationship emerged between Gln consumption and Gln dependency 
(Fig. 2a and Supplementary Fig.3a). In contrast, all cell lines showed a net secretion of Glu 
despite its presence in the medium (Fig. 2b). Tracing 13C5-labeled Gln revealed that 38 ± 
8% to 60 ± 19% (GUVW and U87 cells, respectively) of the Gln consumed was deamidated 
and secreted as 13C5-Glu (Fig. 2a-b). Unexpectedly, even Gln-starved cells discharged Glu 
(Fig. 2b, empty bars). Here, intracellular Gln was almost exhausted (Fig. 2c) and Glu 
concentration fell by more than 50% (Fig. 2d) yet, neither acetyl-CoA (Fig. 2e) nor oleate 
(Fig. 2f) levels were reduced, re-affirming that Gln does not sustain fatty acids biosynthesis 
under normoxic condition16-20. Consistently, in all cell lines, less than 15% of the citrate 
was derived from reductive carboxylation (13C5-Citrate; Supplementary Fig. 3b), and 
labelled acetyl-CoA and oleate were barely detectable (Fig. 2e-f).
To identify the carbon source for Glu synthesis under Gln starvation, Gln-deprived LN18 
and SF188 cells were incubated with 13C6-glucose. In both cases the contribution of glucose 
carbons to Glu was markedly increased (Fig. 2g). Accordingly, alanine consumption was 
increased (Supplementary Fig. 2, inset), providing the nitrogen required for Glu production 
(Fig. 2h). Moreover, a strong direct correlation between Glu efflux and growth inhibition 
was observed (Fig. 2i), suggesting that upon Gln withdrawal, Glu efflux limits the 
intracellular Glu available for reactions essential for growth.
To test whether Glu efflux indeed limited both its availability and the proliferation of Gln-
starved cells, LN18 cells were incubated with sulfasalazine, an inhibitor of , a Glu/
Cystine antiporter (Fig. 2j) which is active in glioma cells15, or with 4 mM Glu, largely 
exceeding the Ki for 21. In both conditions Glu release was largely inhibited (Fig. 2k). 
Consistently, the activation of  by increasing the extracellular concentrations of cystine, 
boosted Glu efflux (Fig. 2k), firmly associating  with the escape of Glu from GBM cells. 
Inhibiting  prevented the drop in intracellular Glu, aspartate, and citrate, caused by Gln 
withdrawal (Fig. 2l-n). The level of glutathione, an alternative metabolic fate for Glu, was 
also substantially decreased upon Gln starvation, and significantly replenished by Glu and 
sulfasalazine (Fig. 2o). However, the drop in glutathione upon Gln starvation was not 
accompanied by its increased oxidation (Supplementary Fig. 3c), indicating that Gln 
delimits Glu availability for glutathione biosynthesis without causing oxidative stress. 
Furthermore, adding the membrane permeable dimethylester of ｳ-ketoglutarate (dm-ｳKG) 
to Gln-starved cells doubled the Glu efflux (Fig. 2k) and replenished Glu, aspartate, citrate 
and glutathione intracellular pools (Fig. 2l-o). Overall, in the absence of Gln,  inhibition 
or dm-ｳKG supplementation restored the cellular Glu, aspartate, citrate and glutathione 
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levels to that of non-starved cells. However, maintaining the levels of these metabolites only 
moderately rescued the proliferation of Gln starved cells (Fig. 2p). Together with the 
observations that, under Gln starvation, intracellular oleate was unaffected (Fig. 2f), and 
glucose-dependent Glu production increased (Fig. 2g-h), these results imply that the 
contribution of Gln to growth is largely independent on anaplerosis.
To evaluate this directly, BPTES, a GLS inhibitor, was employed. The kinetics of Gln-
derived Glu secretion from LN18 and SF188 cells showed that BPTES inhibited GLS 
activity (Fig. 2q). Accordingly, the rate of Gln consumption was reduced (Fig. 2r). 
Nevertheless, at the minimum effective concentration, BPTES did not affect the growth of 
the GBM lines (Fig. 2s and Supplementary Fig. 3d-i) confirming that here, GLS and Gln-
based anaplerosis are dispensable for maximal growth.
Glutamine Synthetase sustains purine availability and cell growth under Gln starvation
Next, a genome-scale constraint-based metabolic modelling approach was employed22, 
searching for reactions that become essential when Gln is removed from the SMEM 
medium. According to the model, GS was the only enzyme essential for sustaining biomass 
production after Gln starvation (Supplementary Note).
Together, GS and GLS control Gln homeostasis by catalysing opposite reactions (Fig. 2j and 
3a). The mRNA levels of GS and GLS in all cell lines revealed no pattern of Gln 
dependency (Supplementary Fig. 4a). While it has been proposed that c-Myc determines Gln 
addiction by increasing GLS expression3,23,24, MYC-induced lung tumours were shown to 
increase GS expression2. In line with this, SF188 cells, harboring MYC amplification25, and 
expressing high levels of c-Myc (Fig. 3b and supplementary Fig. 4a), showed the highest 
levels of GS mRNA and protein (Fig. 3b and Supplementary Fig. 4a). In most cell lines, GS 
protein levels rose upon Gln deprivation (Fig. 3b). Furthermore, GS protein levels tend to 
increase in cells with decreased sensitivity to Gln withdrawal (Fig. 3c). Nevertheless, GS did 
not match the residual low amount of Gln found in Gln-starved cells (Fig. 2c). To 
investigate this apparent discrepancy, the metabolic flux via GS was assessed by the 
incorporation of 15N-labeled ammonia ( ) into Gln in LN18 and SF188 cells, which 
display low and high levels of GS, respectively. Significant levels of 15N-labeled Gln were 
indeed detected in SF188 but not in LN18 cells (Fig. 3d). Next, SF188 and U251 cells, 
displaying high levels of GS and low sensitivity to Gln withdrawal, were incubated with L-
methionine sulfoximine (MSO), a selective irreversible inhibitor of GS. MSO sensitized 
cells to Gln starvation and, further, abolished the protective effect of Glu supplementation 
(Fig. 3e). To complement this approach, GS expression was stably silenced in these cells by 
two shRNA sequences (Fig. 3f). Upon Gln starvation cell proliferation (Fig. 3g) as well as 
colony formation (Fig. 3h and Supplementary Fig. 4b) was lowered by GS silencing. 
Supplementation with the GS substrates Glu and ammonia, rescued Gln-deprived control 
cells more effectively than GS-silenced cells.
To corroborate the causal link between Gln biosynthesis and Gln-dependency, GS was 
overexpressed in LN18 cells, which display low GS levels and high sensitivity to Gln 
deprivation. To this end, LN18-derived clones stably expressing infra-Red Fluorescent 
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Protein only (iRFP)26,27 or iRFP and GS were established. To eliminate intrinsic clonal 
variability, GS expression and its effect on growth under Gln starvation were evaluated in 
multiple clones (6 iRFP and 9 iRFP-GS). After five days of starvation, growth of iRFP 
control cells reached, on average, 16% ± 5 % of control Gln-fed cells, while iRFP-GS clones 
reached on average, 54% ± 12 % (Fig. 4a). Under Gln-supplementation, the iRFP-GS5 clone 
proliferated slower than iRFP controls. This was not rectified by GS inhibition with MSO 
(Fig. 5b), consistent with a reported non-metabolic, anti-proliferative role of GS28. 
Nevertheless, iRFP-GS5, but not control iRFP4 cells, proliferated and formed colonies in 
Gln-free medium and this growth advantage was blocked by MSO (Fig. 4b-c). These results 
imply that under Gln starvation the amidation of Glu via GS sustains cell growth. In line 
with this, when supplemented with 15N1-ammonia, GS-expressing cells displayed 15N 
incorporation into ~50% of the total Gln pool, even when Gln fed (Fig 4d). When incubated 
with 15N1-ammonia without Gln, residual intracellular Gln was higher in iRFP-GS5 cells 
compared to control iRFP4 cells, and produced entirely by GS as judged by 15N 
incorporation (Fig. 4d).
To explore the essentiality and metabolic fate of de novo synthesized Gln under Gln 
starvation, we employed Flux Imbalance Analysis29. In silico, nucleotide biosynthesis 
delimited cell growth, with a higher weighted cost for purine biosynthesis (Supplementary 
Note). Indeed, regardless of GS status, Gln removal only marginally affected the levels of 
the pyrimidine nucleotides uridine monophosphate (UMP) (Fig. 4e). Moreover, the 
contribution of GS-derived 15N1-Gln to 15N1-UMP showed that the low GS-activity in 
iRFP4 cells could maintain UMP production. Similarly, the biosynthesis of UDP-N-
acetylglucosamine, an intermediate of hexosamine biosynthesis, which requires Gln-derived 
nitrogen, was also sustained in iRFP4 cells during Gln starvation (Supplementary Fig. 4c). 
By contrast, 5-Aminoimidazole-4-carboxamide ribotide (AICAR), a purine precursor for 
inosine monophosphate (IMP), dropped to undetectable levels in Gln-starved iRFP4 cells 
(Fig. 4f). The ammonia-derived AICAR (15N2-isotopologue) in Gln-starved iRFP-GS5 cells 
demonstrates that GS contributes the two Gln nitrogen atoms required for its biosynthesis 
(Fig. 4f). Thus, 15N2-IMP accumulated in Gln-deprived iRFP-GS5 cells, but not in iRFP4 
cells (Fig. 4g). The IMP found in iRFP-GS5 starved cells corroborates the reported 
inhibitory effect of Gln deprivation on IMP dehydrogenase30, and suggests that under these 
conditions over-activity of GS exceeds the rate of IMP conversion to AMP and GMP. 
Indeed, AMP levels were not significantly affected by either Gln presence or GS 
overexpression (Fig. 4h). Moreover, ATP and GTP levels, indices of the cell’ s bioenergetics 
state, were comparable between iRFP-GS5 and iRFP4 starved cells (Fig. 4i-j). Conversely 
the fractions of 15N labelled AMP, ATP, and GTP found in iRFP-GS5 cells exceeded those 
of iRFP4 cells, demonstrating that, under Gln starvation, GS sustains de novo biosynthesis of 
purine nucleotides.
Notably, the reduction in IMP caused by Gln starvation in the six GBM cell lines correlated 
with Gln-dependency (Fig. 4k-l). Accordingly, adenosine, but not guanosine or pyrimidine 
nucleosides, partially restored Gln-independent growth of iRFP4 cells (Fig. 4m). 
Furthermore, the combined addition of adenosine and Glu compensated for the lack of 
exogenous Gln in iRFP4 cells (Fig. 4m), and Glu alone completely restored proliferation of 
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iRFP-GS5 starved cells (Fig. 4n). In both lines, MSO prevented the Glu rescue, confirming 
that under Gln starvation Glu availability determines Gln production rather than anaplerosis. 
The effect of adenosine on Gln-starved cells was MSO-independent (Fig. 4m-n), since it 
supported proliferation downstream of GS.
Primary human GBM stem-like cells are self-sufficient for Gln requirements
The clinical relevance of studying established glioma cell lines has been questioned due to 
their inability to form tumours that recapitulate human pathology. Therefore, we utilized 
three primary patient-derived GBM cell lines (E2, R10, R24), generating paired populations 
of differentiated cells (DIFF) and glioma stem-like cells (GSC)31. Stem cell markers such as 
CD133, Olig2 and Sox2, were predominantly expressed in GSC but not DIFF, however the 
astrocytic marker glial fibrillary acidic protein (GFAP), was not consistently associated with 
the DIFF population (Fig. 5a). The expression of GS was markedly higher in all GSC 
compared to DIFF (Fig. 5a) and while DIFF proliferation was attenuated in the absence of 
Gln, GSC grew independently of Gln supplementation (Fig. 5b). Once more, the growth of 
Gln-starved DIFF and GSC was abolished by MSO (Fig. 5b).
Next, the exchange rates (Fig. 5c-d) and intracellular composition of metabolites (Fig. 5e-h) 
were analysed in these primary Gln-starved or control cells, in the presence of 15N1-
ammonia. The net Gln consumption was consistently higher in DIFF compared to GSC, 
whereby R24-GSC demonstrated no net Gln consumption (Fig. 5c). As the 
intracellular 15N1-Gln fraction shows, GSC have higher GS activity compared to DIFF and 
sustain higher residual Gln levels upon starvation (Fig. 5e). The differences in Glu exchange 
rates were also striking: GSC exhibited a net uptake of Glu, while the reverse occurred in 
DIFF (Fig 5d). Also, upon Gln withdrawal, intracellular levels of citrate (Fig. 5g) decreased 
in DIFF, but remained unaltered in GSC, showing that Gln-derived anaplerosis was 
redundant to the stem-like population. Finally ammonia-derived 15N incorporation into 
purine nucleotides (15N2-AMP) under Gln starvation was greater in GSC compared to the 
paired DIFF.
Human GBM tumours rely on in situ de novo Gln synthesis
As shown above, GS activity, largely determining Gln dependency, varies between 
established and primary human GBM cells. Similarly, tissue microarray (TMA) analysis 
showed that GS expression varies between human GBM patients (n=209), resembling a 
Gaussian distribution ranging from tumours with low GS levels, comparable to neurons 
(25% of patients), to high-expression tumours comparable to astrocytes (15%) (Fig 6a-b). 
However, GS expression did not predict patient median survival (Fig. 6c). Of 20 biopsies, 
from which core TMA were sampled, 5 showed substantial intra-tumoral GS 
immunostaining heterogeneity (3 examples are reported in Supplementary Fig. 5). Most 
GBMs either showed GS uniformity, or a mosaic infiltration of GS-positive cells, suggesting 
autonomous intra-tumoral Gln biosynthetic capacity. To assess this hypothesis in human 
tumours, seven GBM patients were injected with 13C6-glucose prior to surgery, and 
metabolites were extracted from the resected tumours and their edematous margins. The 
metabolic analysis reliably discriminated between tumour and adjacent tissues by using the 
choline to creatine ratio, a parameter for classifying brain tumours by MR spectroscopy32 
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(Fig. 6d). No significant difference in Gln content was observed between tumour and 
adjacent tissues (Fig. 6e). At the time of resection, 13C6-glucose enrichment in serums 
ranged between 16% and 50% (Fig. 6f, and Supplementary Fig. 6a). Glucose-derived 13C-
Gln was detected in 6/7 tumours and in 7/7 adjacent edematous tissues with an enrichment 
ranging between 1% and 12% (Fig. 6g). In 3/5 patients the fraction of glucose-derived Gln 
in the tumour was higher than in the serum sample, and so not in equilibrium with the 
circulating Gln, suggesting that the tumour Gln pool is synthesized in situ and/or provided 
by adjacent normal brain.
To complement the analysis in patients, mice were orthotopically transplanted with a GS 
positive human GBM (P3, Fig. 6h) and injected with 13C-labelled glucose or Gln ~20 
minutes prior to tissue extraction. An enrichment of 44 ± 3% of 13C6-glucose was found in 
the blood at the time of tissue sampling. The intracellular hexoses phosphate pool derived 
from 13C6-glucose was ~10% and 5% in tumour and contralateral brain tissue, respectively 
(Fig. 6i). Concomitantly, ~10% and 15% of the total Gln was labelled (13C2) from 13C6-
glucose in tumours and contralateral brain, respectively (Fig. 6i), consistent with GS activity 
in those tissues. After 13C5-Gln injection, the enrichment in circulating 13C5-Gln at the time 
of tissue sampling was 17 ± 1%. Isotopologue distribution analysis showed an enrichment 
in 13C5-Gln of <5% in both tumour and contralateral brain tissues (Fig. 6j), while in the 
liver, 13C5-Gln presented 12% of the total (Supplementary Fig. 6e). Products of 
glutaminolysis, such as Glu and ｳ-ketoglutarate, were labelled below 1% in both tumour and 
brain tissues but ~5% in liver (Fig. 6j and Supplementary Fig. 6e). These results suggest 
slow kinetics both for Gln uptake from the blood, and for glutaminolysis in GBM and brain 
tissues, compared to liver. Similar results were obtained upon constant carotid artery 13C5-
Gln infusion: within two hours, circulating 13C5-Gln levels plateaued at ~20% enrichment, 
with an overall ~70% increase in steady-state levels of Gln (Supplementary Fig. 6f). Here 
too, 13C5-Gln and glutaminolysis products were scarce in tumour and contralateral brain 
(Supplementary Fig. 6h-i) indicating that physiologically, circulating Gln does not 
significantly supply Gln to the brain or the tumour within it.
Next, Erwinase, an enzyme that temporarily depletes circulating asparagine (Asn) and 
significantly reduces Gln9,33 (Fig 7a), was injected daily (five times per week) into mice 
bearing GS-negative orthotopic GBM xenografts (T101, Fig. 7b). Erwinase reduced intra-
tumoral and intracerebral Asn but not Gln (Fig. 7c). The diffuse morphology of GS-negative 
tumours impaired Ex vivo MRI analysis volumetric quantification (Fig. 7d). Histological 
reconstruction to assess tumour burden (Fig. 7e) revealed no significant differences between 
control and Erwinase treated groups (Fig. 7f). Altogether, these results indicate that Gln is 
not provided to GBM by the blood and so, the proximity of GS-positive astrocytes and GS-
negative glioma cells (Fig. 7b and 7g as representatives) suggest that astrocytes may be a 
source of Gln. Indeed, when mice bearing GS-negative GBM xenografts (T407, Fig 7g) 
were infused with 15N1-ammonia into the carotid artery for 4 hours, the fraction of 15N-Gln 
was ~5% in both tumour and contralateral brain tissues (Fig 7h) indicating that they are a 
secluded, autonomous compartment for Gln biosynthesis and utilization, where GS 
expressing cells supply Gln to GS-negative ones.
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Gln-starved GBM cells feed on astrocyte-derived Gln
To assess this potential interaction, rat primary cortical astrocytes were cultured and their 
Gln requirement and metabolism investigated. Similar to GBM cells, the minimal Gln 
concentration required for maximal astrocyte growth was ~0.65 mM (Fig. 8a). Nonetheless, 
astrocyte proliferation was barely affected by Gln deprivation (Fig. 8b). As observed in the 
human TMA (Fig. 6a), GS protein levels in astrocytes and in the highest expressing GBM 
cells were comparable (Fig. 8c). However, only astrocytes demonstrated no net Gln 
consumption but rather, rapid Glu uptake (Fig. 8d-e), in line with the expression of 
Excitatory Amino Acids Transporters (EAAT) in this cell type34. Under Gln starvation, Glu 
consumption was unaffected and paralleled by an equimolar net Gln efflux (Fig. 8d-e). The 
absence of Gln in the medium reduced intracellular Gln, but not Glu (Fig. 8f-g). 
Moreover, 13C6-glucose tracing showed that only 30-40% of both intracellular Glu and Gln 
(Fig. 8f-g) were glucose-derived. Astrocytes maintained ~30% of the control level of 
intracellular Gln under Gln starvation (Fig. 8f and 8h), fitting with high GS expression. Gln 
maintenance depended on GS activity, as seen from both 15N1-ammonia tracing and GS 
inhibition by MSO (Fig. 8h). Moreover, GS inhibition dramatically elevated the intracellular 
amounts of its substrate, Glu (Fig. 8i), without changing the steady state levels of the Gln-
product, AMP (Fig. 8j). However, combined Gln withdrawal and GS inhibition significantly 
reduced the labelled fraction of AMP derived from de novo synthesis (15N2 and 15N3; Fig. 
8j), and hindered proliferation (Fig. 8k).
Finally, in co-culture, astrocytes enabled the proliferation of GS-negative LN18 iRFP4 cells 
without Gln supplementation (Fig. 8l). Moreover, transwell co-culturing of these cells 
showed that the factor conveying growth was diffusible (Fig. 8m-n). The addition of 
Erwinase, which depletes both Asn and Gln, prevented the rescue of Gln-deprived cells by 
astrocytes (Fig. 8m-n). Since Asn was present in the media during all Gln-starvation 
experiments, and since astrocytes consume Asn but produce and secrete Gln (Fig. 8d and 
Supplementary Fig. 6k), these results designate astrocyte-derived Gln as the growth-
supporting factor for Gln-starved GBM cells.
DISCUSSION
Gln plays multiple metabolic and non-metabolic roles. Consequently, the dependency of 
cancer cells on Gln is difficult to discern. Nevertheless, it was demonstrated here that the 
Gln requirement in GBM goes beyond anaplerosis (Fig 2q-s). We identified two alternative 
metabolic determinants for Gln sensitivity: 1) Glu release via the  antiporter and 2) GS-
dependent conversion of Glu to Gln. GS and  seemingly compete for cytoplasmic Glu 
which, during Gln starvation, becomes limiting (Fig. 2d,l). Nevertheless, the rescuing effect 
achieved by maintaining intracellular Glu through  inhibition depends on GS activity 
(Fig. 3e, h, g and Fig. 4m-n). These results demonstrate that upon Gln starvation, Glu 
conversion to Gln constitutes a critically limiting reaction required for growth. This 
metabolic trait applies to established GBM lines, and to naïve primary cells. Indeed, when 
primary GBM cells were maintained in a stem-like state, GS expression was dramatically 
increased (Fig. 5a) and Glu was taken-up rather than released (Fig. 5d). Both responses 
enable growth of glioma stem-like cells independent of extracellular Gln (Fig. 5b). The fate 
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of newly-synthesized Gln in both established and primary GBM cells was followed by 15N1-
ammonia tracing, identifying AMP biosynthesis pathway as a significant player in Gln 
dependency (Fig. 4 d-j and Fig. 5h).
GS is found in the majority of human GBM (Fig. 6a-b), its expression associated with poor 
prognosis35 though this is not supported by our TMA study. However, we show that GS 
expression varies greatly between tumours, ranging from negative, comparable to GS 
expression in neurons, to high, as in normal astrocytes. This variation accords with a Gln-
rich tumour microenvironment, which alleviates the need to synthesize Gln. Nevertheless, in 
agreement with previous reports36,37, it is shown here that most human GBM, as well as 
GS-proficient orthotopic GBM xenografts, withdraw carbons from the TCA cycle 
(cataplerosis) to synthesize Gln via GS. When compared to the liver, GBM are inclined 
towards net Gln synthesis, rather than glutaminolysis (Fig. 6i and Supplementary Fig. 6d). 
Accordingly, the circulation provides minimal amounts of Gln to normal brain38 and GBM 
(Fig 6l and Supplementary Fig. 6f, h, i). Moreover, a marked decrease in circulating Gln 
levels did not affect tumour growth (Fig 7a-h) and, GBM expressing low GS had levels of 
ammonia-derived Gln comparable to contralateral brain (Fig. 7j). The stability of Gln levels 
may explain the heterogeneity in GS expression between patients (Fig 6b) and within some 
tumours (Supplementary Fig. 5): GS-positive astrocytes and/or GBM cells (potentially GSC) 
excrete Gln that supports the growth of GS-negative GBM cells. Indeed, primary astrocytes 
in culture retain the metabolic traits of Glu uptake, GS-dependent Gln synthesis and Gln 
secretion, and support the proliferation of GS-negative, Gln-auxotrophic GBM cells (Fig 8l-
n). Thus, this brain-to-tumour metabolic communication portrays a scenario in which Gln, 
provided by astrocytes, feeds GS-negative cancer cells (Fig. 3g). Indeed, GS-positive 
cellular protrusions of astrocytes surround GS-negative GBM cells in orthotopic xenografts 
and human tumours (Fig 7b, g and Supplementary Fig. 5p). This ‘ parasitic’  behaviour of 
cancer cells could divert the physiological Gln-Glu cycle in the brain and, indeed, an 
increase in epileptic seizures has been reported for patients with GBM expressing low GS39.
METHODS
Cell cultures
The human glioblastoma cell lines MOG-G-UVW, LN-18, LN-229, SF-188, U-251 MG, 
U-87 MG (hereafter referred to as GUVW, LN18, LN229, SF188, U251, U87, respectively) 
were obtained from the following sources: GUVW: frozen stock originally isolated by Dr 
Ian Freshney at the University of Glasgow; LN18 and LN229: ATCC; SF188: Brain Tumour 
Tissue Bank University of California San Francisco; U251 and U87 were kindly given by 
Prof Kevin Ryan and Prof Anthony Chalmers, respectively. The cell lines were 
authenticated using Promega GenePrint 10 system (STR multiplex assay that amplifies 9 
tetranucleotide repeat loci and the Amelogenin gender determining marker). No cell line 
used in the manuscript has been found in the ICLAC database of commonly misidentified 
cell lines. Cortical Astrocytes were generated from the cortex of P7 Sprague-Dawley rat 
pups (unclassified gender). Briefly both cortices were removed from each pup cleared of 
meninges and enzymatically dissociated and purified as previously described. Tissue from 2 
pups was added to each 75cm2 tissue culture poly-L-Lysine coated flask (13μg/ml, Sigma). 
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Astrocytes prepared in this way were over 95% pure as assessed by immunoreactivity to 
glial fibrillary acidic protein41.
All the cell lines tested negative for mycoplasma with MycoAlert™ when tested with 
Mycoplasma Detection Kit (Lonza). Cells were maintained in DMEM (Invitrogen 
21969-035) supplemented with 2 mM Glutamine and 10% FBS. All the experiments were 
performed on cells seeded and incubated for at least 24h in a serum-like medium, SMEM, 
formulated as reported in Supplementary Table 1, and supplemented with 10% FBS, 
dialyzed against a semi-permeable cellulose membrane (3.5kDa MW cutoff).
For co-culture experiments 30,000 astrocytes /well were plated in a 24 well plate and 
allowed to grow to confluence, then LN18-derived clone stably expressing infrared 
fluorescent protein, iRFP4, was plated 25,000 cells/well or 5000 iRFP4 cells/transwell 
(Costar, CLS3413) were seeded in complete medium for direct or transwell co-culture 
experiments, respectively. The day after iRFP4 cell cultures were extensively washed with 
PBS, a transwell was inserted in wells containing astrocytes, and medium was replaced with 
the conditions indicated in Figure 8l, n. Half of the medium volume was renewed daily for 
the whole duration of the experiments. Growth was assessed by measuring fluorescence with 
a Licor Odyssey scanner and quantified Image Studio 2.0 software.
E2, R10 and R24 human glioblastoma cells were obtained and cultured as previously 
reported with minor modifications31. In brief differentiated (DIFF) cells were maintained in 
advanced DMEM/ F-12 (Gibco) supplemented with 10% FBS and 2mM L-Gln, while 
glioma stem-like cells (GSC) were maintained in advanced DMEM/F-12 supplemented with 
B27 (1%, Invitrogen), N2 (0.5%, Invitrogen), 4 μg/ml heparin, 20 ng/ml fibroblast growth 
factor 2 (bFGF, Sigma), 20 ng/ml epidermal growth factor (EGF, Sigma), 1mM pyruvate, 
and 2mM L-Glutamine. For all the experiments stem cells were seeded and incubated in 
SMEM supplemented as described above, while DIFF cells were seeded and incubated in 
advanced DMEM/F-12 supplemented with 10% dialyzed FBS. 0.65mM Glutamine was 
added as indicated in figures.
Cell number assessment
Cells were plated at a density of 20000 cells/well in 24 well plates. Cell number was 
assessed at the specified experimental time as follows: each well was washed twice with 
PBS, trypsinized, cells were re-suspended in a Casyton solution and counted with a Casy 
cell counter. The Doubling Time (DT) was obtained using the Exponential Growth equation 
with GraphPad prism 5.0. The % of growth inhibition was calculated according to the 
following equation: 
Cell death assessment
Cells were plated at a density of 15000 cells/well in 12 well plates. After 2 days cells were 
placed in medium with or without glucose and Gln, and supplemented with CellTox™ Green 
Dye (1:1000, Promega, G8731). Cells were incubated in an IncuCyteTM FLR 
(EssenBioScience) for 72h, during which time bright field and fluorescence pictures were 
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taken every 15 minutes. For each time point a cell death index was calculated by dividing 
the number of dead cells on the confluency index.
Cell cycle analysis
Culture media and cells were collected, centrifuged and washed with PBS. Cells were then 
fixed with cold methanol and stained with a PBS solution containing propidium idodide 
(100μg/ml) and RNAase A (250 μg/ml). DNA nuclear content was measured by using a 
Beckton Dickinson FACScan flow cytometer and data analyzed with the FlowJo software.
Tissue Microarray (TMA) and immunohistochemistry (IHC)
The collection of human biopsy tissue was approved by the regional ethical committee at 
Haukeland University Hospital, Bergen, Norway (REK 013.09). All patients gave a written 
informed consent for tumour biopsy collection and signed a declaration permitting the use of 
their biopsy specimens for research. Core tissue of glioblastoma cancer tissue (n=209) were 
identified by a pathologist, and collected from representative areas of tumours derived from 
patients’  surgical resection. Tissue cores were collected in triplicate for each patient. 
Follow-up details including date and cause of death were collected. For IHC analysis of the 
TMA, and mouse brain slices, the following procedure was followed. Epitope retrieval was 
performed at 98°C for 15’  in citrate buffer, pH 6. The immunostaining was performed using 
an EnVision System-HRP DAB (Dako, K4006). The cores were incubated over night with 
primary antibody. Cores were counterstained with haematoxylin, dehydrated and 
coverslipped. The staining was quantified using a weighted histoscore method with a final 
value range 0–300. The intensity of the immunostaining observed for normal astrocytes was 
classified as 300 and used as reference. Low- medium- and high-Glutamine Synthetase (GS) 
expressing groups were defined as reported in Figure 6b. For TMA and IHC the following 
antibodies were diluted in a solution of 5% BSA in TBS-tween and employed at the 
specified dilutions: purified mouse anti-human monoclonal GS antibody (BD transduction 
laboratories, Cat. 610518, clone 6 at a final concentration of 250ng/ml); mouse monoclonal 
anti-human nestin antibody (Abcam ab6320, clone 3k1, 1:500); mouse monoclonal anti-
human EGFR antibody (Dako 7239 clone E30, 1:200, 1h at room temperature). For tumour 
volume quantification by IHC the mouse brain was paraffin embedded and entirely sliced 
into sections of 8μm. Two sections were loaded on each slide, and one slide in every 10 was 
stained for EGFR. Digital images were acquired with a Leica SCN400 Slide scanner, loaded 
into Matlab, calibrated and pixels positive for the staining were identified and used to 
quantify tumour volume. All IHC staining shown are representative of three or more 
sections.
Metabolic study in GBM patients
Before undergoing surgical tumour resection, seven GBM patients were infused for 15 
minutes with 20 gr of 13C6-Glucose. During the operation tissue fragments from the core 
and peripheral region of the tumour were stereotactically sampled (~200 mg for each 
region). On average the specimens were snap-frozen 47 minutes after the end of the glucose 
injection (range 30-80 minutes). Peripheral blood samples were also collected at the same 
time of tissue sampling. Sub-fragments of frozen tissues (15-25 mg) were further dissected 
from peripheral and core regions of the tumour, and from edematous adjacent tissue. The 
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samples were extracted on dry ice and processed as described below for human orthotopic 
GBM xenografts.
Informed consent was obtained from all human subjects involved in the study, the heavy 
isotope administration and the collection of tissue from surgical resections was approved by 
the regional ethical committee at Haukeland University Hospital, Bergen, Norway (REK 
2010/130-2).
Primary orthotopic human GBM xenografts
Patient derived GBM xenografts were generated as previously reported42,43. Briefly, GBM 
patient-derived spheroids were stereotactically implanted into the right frontal cortex of 8-12 
weeks old, male and female, NOD-SCID mice (Charles River, Lyon) using a Hamilton 
syringe (Hamilton, Reno, USA). After 4-6 weeks P3 GBM tumour was fully established in 
the brain, and U-13C6-glucose or U-13C5-glutamine (Cambridge Isotope Laboratories, 
Tewksbury, MA) were injected as a bolus in the tail vein at a dose of 1mg/gr and 0.15mg/gr 
of body weight respectively. 22 minutes after injection the animals were euthanized, organs 
were dissected, and tumour and contralateral brain fragments were snap frozen. For 
intracarotid infusion the mice were kept under anesthesia with ketamine medetomidine 
isoflurane and underwent surgical procedure to expose the right carotid artery. 
4.7μmoles/Kg/min of 15N1 ammonia was infused 0.833μl/min for 4h in NOD SCID mice 
(Charles River, Lyon) xenografted orthotopically with T407 GBM. 13μmoles/kg/min 
of 13C5-glutamine were infused 0.125μl/min for 4h in 8-weeks old, female, Swiss Nu/Nu 
mice (Charles River, Lyon) xenografted orthotopically with the GS-positive T16 GBM. To 
assess the effects of Erwinase, 8-weeks old, female, Swiss Nu/Nu mice (Charles River, 
Lyon) were implanted with T101 tumour spheroids (six/mouse). 42 days after implantation 
mice were randomly assigned to Erwinase treatment or control group. Erwinase was injected 
intraperitoneal 5U/gr of body weight, five times / week. The treatment continued for 6 
weeks. Mice of the control group were intraperitoneally injected with saline solution. Mice 
were euthanized six hours after the last injection and tumour and contralateral brain 
fragments were snap frozen for metabolic analysis. Whole brains were immediately fixed in 
4% paraformaldehyde for ex vivo MRI. For metabolic analysis, 10-20mg of tissue were 
extracted with a beads mill (Qiagen, Tissuelyzer) in a solution containing 20% water, 50% 
Methanol, 30% Acetonitrile (25μl of extraction solution/mg tissue). The extracts were spun 
down at 16000g for 10 min and supernatants stored −80°C for LC-MS analysis. Human 
glioblastoma biopsies were obtained from the Neurosurgery Department of the Centre 
Hospitalier in Luxembourg (CHL). All patients had provided written informed consent, with 
procedures that were approved for the project (project number: REC-LRNO-20110708) by 
the National Research Ethics Committee for Luxembourg (CNER). The handling of the 
animals and the surgical procedures were performed in accordance with the European 
Directive on animal experimentation (2010/63/EU) and the national regulations of 
Luxembourg and the local ethical committee (the Animal Welfare Structure (AWS) LIH) 
approved the protocol (protocol number: LRNO-2014-06).
MRI analysis—At the end of Erwinase treatment the brains of the 20-weeks old Swiss 
Nu/Nu mice with T101 tumours (7 female mice/group) were harvested and fixed in 4% 
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paraformaldehyde. Ex vivo scans were acquired on a 7T micro-MRI system (Bruker 
PharmaScan) using a mouse brain volume coil. The T2-weighted MRI protocol used a Fast 
Spin Echo sequence with TE = 36 ms, TR = 4300 ms, and 63 μm in plane resolution. The 
Diffusion Weighted Imaging (DWI) sequence used EPI readout with TE=28.5ms, 
TR=7000ms and b-values ranging from 500 to 6000 s/mm2 in 3 directions. The tumours 
were independently delineated by two users (A.O. and O.K.) using Paravision 5.0 (Bruker; 
Ettlingen, Germany).
Immunoblotting
Cells were washed twice with cold PBS and lysed in RIPA buffer (20 mM Tris-HCl, pH 7.5, 
150 mM NaCl, 1 mM EDTA, 1mM EGTA, 1% Triton, 2,5mM sodium pyrophosphate, 1mM 
glycerophosphate) supplemented with 1mM Na3VO4, 1mM NaF and protein inhibitor 
cocktail. Protein concentration was determined with the bicinchoninic acid assay (Thermo 
scientific) using BSA as a standard. Equal amounts of protein were mixed with Laemmli 
buffer 4× (250 mM Tris-HCl, pH 6.8, 8% SDS, 40% glycerol, 0.4 M DTT), warmed at 95°C 
for 5 min, and loaded on 10% gels for SDS-PAGE. After electrophoretic separation, proteins 
were blotted onto 0.22 mm nitrocellulose membrane (Millipore), blocked with 5% non-fat 
milk in TBS-Tween, and incubated at 4°C overnight with the following antibodies: 
Glutamine Synthetase (BD Transduction Labs, 610517, clone 6, 1:1000), ｴ-tubulin (Sigma 
Aldrich, T5201, clone AA2, 1:5000), GLS (Abcam, ab60709, 1:1000), c-Myc (Cell 
Signalling Technology, 5605, clone D84C12, 1:1000) Glial Fibrillary Acidic Protein (Dako, 
Z0334, 1:10000), SOX2 (Abcam, ab75485, clone 57CT23.3.4, 1:1000), CD133 (Miltenyl 
Biotec, W6B3C1, clone W6B3C1, 1:1000), Olig2 (R&D system, AF2418, 1:500), Actin 
(Santa Cruz Biotechnology, sc-1616-R, 1:1000). Membranes were then washed and 
incubated with secondary donkey anti-rabbit (Licor 926 32213, 1:10000) or donkey anti-
mouse (Licor 926 32212, 1:10000). The IR scanning was performed using a Licor Odyssey 
scanner and acquired using Image Studio 2.0. All western blots shown are representative of 
two experiments unless otherwise indicated.
qPCR analysis
For qPCR analysis 1 μg of total RNA was isolated from cells with RNeasy Mini Kit 
(Qiagen) and retro-transcribed into cDNA using M-Mulv Reverse Transcriptase and random 
hexamers. qPCR reactions were performed using a Fast Sybr Green Master Mix (Applied 
Biosystems), 0.5 mM primers, ROX dye, and a 25ng of cDNA in a final volume of 20 μl 
according to the manufacturer’ s instructions. The following primers were used MYC_F 
CACCAGCAGCGACTCTGA, MYC_R GATCCAGACTCTGACCTTTTGC; GS_F 
TCATCTTGCATCGTGTGTGTG, GS_R CTTCAGACCATTCTCCTCCCG; GLS_F 
GAAATTCGGAACAAGACTGTG, GLS_R AACTTCGATGTGTCCTTCAC ｴ-actin_F 
TCCATCATGAAGTGTGACGT, ｴ-actin_R TACTCCTGCTTGCTGATCCAC. The 
following PCR steps were performed on the 7500 Fast Real-Time PCR System (Life 
Technologies Corporation), 15 min at 95°C followed by 40 cycles of 10 s at 94°C, 30 s at 
55°C, 30 s at 72°C. A 10 min final step at 72°C was performed to visualize the PCR 
products by means of the melting curves. The expression levels of the indicated genes were 
calculated using the ΔΔCT method using actin for normalization.
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Metabolites Extraction and HPLC-MS
The established cell lines were plated in 6 well plates in complete DMEM from 125000 to 
250000 cells / well. After 24h the medium was replaced with SMEM supplemented with 
10% dialyzed FBS. Stem-like and differentiated primary glioma stem cells were plated at 
150000 cells / well in 6 well plates in SMEM supplemented as described in the cell culture 
section. When optimal confluence was reached (1-3 days) 3 wells were extracted as 
described below, and the protein determined (μg prott0). The media in the remaining wells 
was changed with 2 or 7 ml/well of complete SMEM for the analysis of metabolites present 
in the medium or in the cells, respectively. U-13C5-Gln (0.65 mM, Cambridge Isotopes), 
U-13C6-Glucose (5.56mM, Cambridge Isotopes), or 15N1-Ammonia (0.8mM Sigma) were 
supplemented as indicated in figures. Cells, as well as parallel cell-free wells, were 
incubated for 24h at 37°C. At the end of the incubation, an aliquot of the media was diluted 
in a solution containing 20% water, 50% Methanol, and 30% Acetonitrile. The medium 
derived from wells devoid of cells, was used to estimate the exchange rates of metabolites. 
For the profiling of intracellular metabolites, monolayers were rapidly washed 3 times with 
ice-cold PBS and extracted with an aqueous solution of 50% Methanol, and 30% 
Acetonitrile. Both media and cell extracts were centrifuged 16000g for 10min at 4°C and the 
supernatants were analyzed by means of HPLC-MS. The extracted cell monolayer was used 
for protein determination (μg prott24) with a Lowry assay. Aliquots of freshly prepared 
SMEM, without FBS, and spiked with known concentrations of lactate were processed in 
parallel and used as a reference for metabolite quantification. The secretion/consumption 
rate for a specific metabolite (x) was obtained according to the equation 
 where Δ metabolite = [(x)nmol medium with no cell – (x)nmol 
medium with cells]. For the LC separation of medium samples a ZIC-HILIC (SeQuant) with 
a guard column (Hichrom) was used. The mobile phase A was a 0.1% formic acid solution 
in water and mobile phase B was 0.1% formic acid in acetonitrile. The flow rate of mobile 
phases was kept at 100 μl/min and gradient was as follows: 0 minutes 80% of B, 12 minutes 
50% of B, 26 minutes 50% of B, 28 minutes 20% of B, 36 minutes 20% of B and 37 37 to 
45 minutes 80% of B. For the separation, cell extracts were injected on a ZIC-pHILIC 
column with a guard column. Mobile phase C: 20 mM ammonia carbonate plus 0.1% 
ammonia hydroxide in water. Mobile phase D: acetonitrile. The flow rate was kept at 100 
μL/min and gradient as follows: 0 minutes 80% of D, 30 minutes 20% of D, 31 minutes 80% 
of D and 45 minutes 80% of D. The Exactive Orbitrap mass spectrometer (Thermo 
Scientific, Waltham, MA, USA) was operated in a polarity switching mode.
Cell transfection and infection
For stable transfection 10 cm dishes of 80% confluent LN18 cells were incubated for 9h 
with 10 ml of FBS-free transfection medium containing 1μg/ml of DNA (Vector containing 
P2A-iRFP IRES puro only or GS-P2A-iRFP IRES puro and 2μl/ml of Lipofectamine2000 
(Invitrogen). The transfection mixture was than replaced with 10ml of complete DMEM. 
The following day medium was changed and cells were cultured for 3 weeks in selection 
medium containing 2μg/ml of puromycin. Fluorescent colonies were visualized with the 
Licor Odyssey scanner, picked and amplified in selection medium to obtain stable cultures. 
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For the establishment of cell lines expressing shRNA against Glutamine Synthetase (GS) 
four human unique 29mer shRNA constructs and scrambled negative control non effective 
shRNA cassette (NTC) in lentiviral GFP vector were employed according to the 
manufacturer’ s instructions (TL312740a: GGTGAGAAAGTCCAGGCCATGTATATCTG; 
TL312740b: GAATGGTGCAGGCTGCCATACCAACTTCA; TL312740c: 
TGGTACTGGAGAAGGACTGCGCTGCAAGA; TL312740d: 
GGCACACCTGTAAACGGATAATGGACATG; TR30021ntc: 
GCACTACCAGAGCTAACTCAGATAGTACT, Origene). TL312740b TL312740d and 
TR30021ntc are reported in the manuscript as shGS-1 shGS-2 and shNTC respectively. 
Briefly, lentiviruses were produced by co-transfecting HEK293T cells with each shRNA 
plasmid, lentiviral plasmid psPAX2-1, and packaging plasmid pVSV-G-1, according to a 
standard calcium phosphate procedure. Supernatants containing virus were collected, filtered 
and frozen in stocks at −80°C. For infection of recipient cells the supernatant was thawed, 
mixed with Hexadimethrine bromide (Sigma, H9268, 8μg/ml) and incubated for 24 hours 
with the cells. Infected cells were selected for 2 weeks in medium containing 1-3μg/ml 
puromycin.
Colony forming assay
iRFP and iRFP-GS expressing cells were plated at 300cells/well in 6 wells plates in 
complete SMEM, in the absence or presence of 0.65mM Gln and 1mM MSO as indicated. 
After 3 weeks, colonies were fixed with trichloroacetic acid, stained with SRB and plates 
were scanned using a Licor Odyssey scanner. Images were acquired using Image Studio 2.0. 
SF188 and U251 cells expressing shNTC and shGS sequences were plated at 500 and 350 
cells/well in 6 wells, respectively. Cells were incubated in complete SMEM and 
supplemented as indicated in Figure 3 legend. 12-17 days after seeding colonies were fixed, 
stained, and representative images obtained as described above. For the quantification of 
colonies surface area an ImageJ macro was designed and run. The values obtained from the 
macro were normalized for the exact number of days cells were incubated, and presented as 
% of relative control.
Reagents
U-13C5-L-Glutamine and U-13C6-D-Glucose (Cambridge Isotopes Laboratories, Inc 
CLM-1822, CLM-1396 respectively), 15N1 Ammonium Cloride (Sigma Aldrich 299251), 
sulfasalazine (Sigma Aldrich S0883), MSO (Sigma Aldrich M5379), compound 968 
(Calbiochem 352010, dissolved 10mM in DMSO), BPTES (Sigma Aldrich SML0601, 
dissolved 10mM in DMSO) Erwinase (Eusa Pharma, an international division of Jazz 
Phamaceuticals), all L-amino acids, nucleosides, and nitrogenous bases utilized in the study 
were obtained from Sigma Aldrich.
Genome-scale constraint-based metabolic modeling
A Detailed description of metabolic modelling methods and results is provided in the 
Supplementary note.
Tardito et al. Page 15
Nat Cell Biol. Author manuscript; available in PMC 2016 June 01.
 Europe PM
C Funders A
uthor
 M
an
u
scripts
 Europe PM
C Funders A
uthor
 M
an
u
scripts
Statistical Methods
No statistical method was used to predetermine sample size. For the animal studies, the 
experiments were not randomized, and the investigators were not blinded to allocation 
during experiments. The number of independent experiments performed is reported in figure 
legend. For experiments performed once or twice the raw data of independent repeats are 
provided in the statistics source data. Error bars represent standard error of the mean 
(S.E.M.). Two-tailed Student’ s t, Pearson correlation test, and Log-rank (Mantel-Cox) test 
were performed with Graph Pad Prism 5.0.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Gln starvation reduces GBM cell proliferation. (a) Dose-response curves for cell lines 
incubated for 3 days in DMEM or SMEM with the indicated concentrations of Gln. (b) Cells 
were incubated for the indicated times in SMEM +/− Gln. (c) Cells were incubated for 72 
hours in SMEM +/− Gln or Glucose as indicated. Each dot represents the number of dead 
cells (with plasma membrane integrity loss) normalized over a confluence index. The 
resulting cell death index was assessed every hour. (d) Cell cycle distribution of cell lines 
incubated for 3 days +/− Gln. Mean of 3 independent experiments is shown in 
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Supplementary Figure 1b. (e) Growth inhibition caused by Gln starvation. Mean ± S.E.M. 
n=3 independent experiments. (f) Scatter plot of the doubling time obtained for the cell lines 
in Gln-fed conditions, in relation to growth inhibition caused by Gln starvation. Mean ± 
S.E.M. n=3 independent experiments. (a-d) Data derive from one experiment performed 
twice (a, b, c), or three times (d). Raw data of independent repeats are provided in the 
statistics source data Supplementary Table 5.
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Figure 2. 
The effects of Glu secretion, and GLS inhibition on GBM cells growth and metabolism. (a-
b) Cells were incubated for 24h +/− 13C5-Gln. Secretion (positive bars) and consumption 
(negative bars) rates of Gln and Glu isotopologues are shown. Mean ± S.E.M. n=3 
independent experiments. (c-f) Cells were incubated as in (a-b) and the levels of intracellular 
Gln, Glu, Acetyl CoA, and oleate isotopologues are shown. Mean ± S.E.M. n=3 independent 
experiments. (g-h) LN18 and SF188 cells were incubated for 24h +/− Gln in media where 
glucose (g) or alanine (h) where fully replaced by 13C6-glucose or 15N1-alanine respectively. 
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The isotopologues distributions of Glu released in the medium are shown. Mean ± S.E.M. 
n=3 independent experiments. (i) Scatter plot of Glu secretion observed in the absence of 
Gln, in relation to the growth inhibition caused by Gln starvation. Mean ± S.E.M. n=3 
independent experiments. (j) A schematic representation of the  activity in the context of 
Glu metabolism. Adapted from Bannai et al.40 (k) LN18 cells were incubated for 24h +/− 
Gln in media supplemented or not with Glu, ｳ-ketoglutarate dimethylester (dm-ｳKG), 
sulfasalazine (SSZ), or cystine, at the indicated concentrations, and the secretion/
consumption rates of Glu are shown. (l-o) LN18 cells were incubated as in (k) and the 
intracellular levels of Glu (l), aspartate (m), citrate (n), and reduced form of glutathione (o) 
are shown as % of untreated control. (p) LN18 cells were incubated for 72h as described for 
(k). Cell number is shown as % of untreated control. Mean ± S.E.M. n=4 independent 
experiments. p values refer to a two-tailed t test for unpaired samples. (q-r) Cells were pre-
incubated in medium with 0, 2.5, 5, 10, 15, 30μM BPTES for 3h. At t=0 medium was 
replaced with one containing 13C5-Gln. The abundance of 13C5-Glu (q) or 13C5-Gln (r) in 
the medium was monitored over time. In all conditions cells were exposed to 0.3% DMSO. 
(s) Cells were incubated in medium +/− 2.5μM BPTES for 72h, and counted. DMSO was 
0.3% in all conditions. Mean ± S.E.M. n=3 independent experiments. (k, l, m, n, o, q, r) 
Data derive from one experiment performed once (k, l, m, n, o), or twice (q, r). Raw data of 
independent repeats are provided in the statistics source data Supplementary Table 5.
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Figure 3. 
GS sustains cell growth during Gln starvation. (a) GS and GLS catalysed reactions. (b) Cells 
were incubated for 24h +/− Gln and protein expression was assessed. Unprocessed scans of 
western blots are shown in Supplementary Figure 8. (c) Scatter plot of GS protein 
expression observed in Gln-fed condition (Arbitrary Units, AU) in relation to the growth 
inhibition caused by Gln starvation. Mean ± S.E.M. n=3 independent experiments. (d) LN18 
and SF188 cells were incubated for 24h +/− Gln in the presence of 0.8 mM . The 
intracellular levels of Gln isotopologues are shown as % of 15N0-Gln in LN18 cells. Data 
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derive from one experiment performed twice. Raw data of independent repeats are provided 
in the statistics source data Supplementary Table 5. (e) SF188 and U251 cells were 
incubated for 72h +/− Gln in medium supplemented with 4mM Glu and 1mM MSO as 
indicated. Cells numbers are shown as % of untreated control. Mean ± S.E.M. n=3 
independent experiments. (f) SF188 and U251 cells stably expressing a non-targeting 
control shRNA (shNTC) or two sequences targeting GS (shGS-1 and shGS-2) were 
incubated for 24h +/− Gln. (g) Cells were incubated for 72h +/− Gln in medium 
supplemented with 4mM Glu, and 0.8mM , as indicated. Cell number is shown as % of 
the respective Gln-fed control. Mean ± S.E.M. n=3 independent experiments. (h) Cells were 
incubated for 12-17 days +/− Gln in medium supplemented with 4mM Glu, and 0.8mM 
 as indicated. Colonies obtained in representative wells are shown. n=4 independent 
experiments, quantified as shown in Supplementary Figure 4b.
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Figure 4. 
GS activity regulates cell growth and purine availability under Gln starvation. (a) Top: 
LN18 clones stably expressing iRFP or iRFP-GS were incubated +/− Gln for 5 days and 
protein expression assessed. Unprocessed scans of western blots are shown in 
Supplementary Figure 8. Bottom: For each clone growth was determined from the protein 
amount and referred as % of respective control. Dashed lines show the mean % values 
obtained - Gln. (b) iRFP4 and iRFP-GS5 cells were incubated for the indicated times in 
medium +/− Gln and MSO (1mM), and counted. (c) iRFP4 and iRFP-GS5 cells were 
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incubated +/− Gln and MSO (1mM) for 21 days, and colonies in representative wells are 
shown. Data derive from one experiment performed twice. (d-j) iRFP4 and iRFP-GS5 cells 
were incubated +/− Gln for 24h in medium supplemented with 0.8 mM . The 
intracellular isotopologues of Gln, UMP, AICAR, IMP, AMP, ATP, and GTP are shown as 
% of values obtained for the 15N0 metabolites in iRFP4 cells in the presence of Gln. (k) Cell 
lines were incubated +/− Gln for 24h and the relative amount of intracellular IMP is shown. 
Mean ± S.E.M. n=3 independent experiments. (l) Scatter plot of the changes in intracellular 
IMP levels in relation to the growth inhibition caused by Gln starvation. Mean ± S.E.M. n=3 
independent experiments. (m-n) iRFP4 (m) and iRFP-GS5 (n) cells were incubated for 72h 
+/− Gln in medium containing adenosine (A) guanosine (G) cytidine (C) thymidine (T) 
uridine (U), each at 0.2mM, or in combination (AGCTU) at 0.2 mM each, Glu (4mM), MSO 
(1mM), as indicated. Cells numbers are shown as % of untreated control. Dashed lines show 
percentage values obtained in the absence of Gln without any further supplementation. Mean 
± S.E.M. n=3 independent experiments. (a, b, d, e, f, g, h, i, j) Data derive from one 
experiment performed once (a, b) or twice (d-j). Raw data of independent repeats are 
provided in the statistics source data Supplementary Table 5.
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Figure 5. 
Gln metabolism in differentiated (DIFF) and GBM Stem-like (GSC) primary human GBM 
cells. (a) Protein expression was assessed in E2, R10 and R24 cells maintained in DMEM/
F-12 and supplemented as described in the Methods section. Arrow points to SOX2 specific 
band. A representative experiment repeated twice is shown. Unprocessed scans of western 
blots are shown in Supplementary Figure 8. (b) Cells were incubated in SMEM 
supplemented as described in the Methods section, +/− 0.65mM Gln and 1mM MSO as 
indicated. Mean ± S.E.M. n=3 independent experiments. (c-d) The exchange rates of Gln (c) 
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and Glu (d) isotopologues in cells incubated for 24h in SMEM +/− 0.65mM Gln 
supplemented with of 0.8mM . Mean ± S.E.M. n=3 independent experiments. (e-h) 
The Intracellular content of Gln (e), Glu (f), citrate (g), and AMP (h) isotopologues in cells 
incubated as in (c-d). Mean ± S.E.M. n=3 independent experiments.
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Figure 6. 
Gln metabolism in GBM patients and primary orthotopic xenografts. (a) GBM tissue 
microarray. GS immuno-staining of representative tissue cores at low and high 
magnification (top and bottom respectively). A: Astrocyte, N: Neuron. (b) Frequency 
distribution of GBM patients (n=209) divided according to their histoscore for GS, and 
categorized as low, medium, and high. Normal astrocytes were used as a reference for 
defining maximal immunoreactivity. (c) Kaplan Meier curves for GBM patients divided into 
low, medium, and high GS expression. p value refers to a log-rank (Mantel-Cox) test. (d-e) 
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creatine, choline, choline to creatine ratio (d), and Gln (e) levels in tumor tissue and adjacent 
edematous brain of GBM patients injected with 13C6-glucose before surgical intervention. 
n= 7 patients, p values refer to a two-tailed t test for paired samples. (f-g) 13C6-glucose (f), 
and 13C Gln (g) enrichment in serum at time of tumour resection, in tumor tissue, and in 
adjacent edematous tissue. Gln isotopologues incorporating one or more 13C-atoms, over the 
total amount of Gln detected (% of total) are shown. na: not available, nd: not detectable. 
Values were corrected for the natural abundance of 13C. (h) Coronal section of human P3 
GBM xenograft grown in brain of immunocompromised mice, and stained for human nestin 
and GS. Lower panels are magnification of the respective framed regions. A: astrocytes, AF: 
astrocytic end-feet, N: neuron, V: blood vessel. (i, j) Isotopologue distribution of 
metabolites (Hexose phosphates, citrate, ｳ-KG, Glu, Gln) obtained in mice orthotopically 
xenografted with human P3 GBM, and injected in the tail vain with a bolus of 13C6-Glucose 
(i) or 13C5-Gln (j). Tissues were sampled 22min after injection. The values are mean ± 
S.E.M. n=3 mice for all conditions, except for contralateral brain of mice injected with 
glucose, where 2 mice were used. (i, j) Raw data of independent repeats are provided in the 
statistics source data Supplementary Table 5.
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Figure 7. 
Glutamine supply for GBM tumours with low GS expression. (a) Gln and Asn levels were 
measured by HPLC-MS in peripheral blood samples obtained at indicated time points from 
immunocompromised mice intraperitoneally injected with Erwinase (5U/gr of body weight). 
Mean ± S.E.M. n=5 mice. p values refer to a two-tailed t test for paired samples. (b) Coronal 
section of human T101 GBM xenograft grown in brain of immunocompromised mice, and 
stained for human nestin and GS. Left panels are magnification of the respective framed 
regions. A: astrocytes, N: neuron. (c) Immunocompromised mice were orthotopically 
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implanted with T101 GBM tumours and treated with Erwinase for 6 weeks as described in 
the Methods section. Asn and Gln were assessed in the tumour and contralateral brain 6h 
after the last Erwinase injection. Mean ± S.E.M. n=3 mice. (d) MRI-based Apparent 
Diffusion Coefficient (ADC) maps of T101 GBM tumours treated with Erwinase as 
described in (c). The tumour mask has been manually delineated to highlight the tumour 
region. IHC staining of brain sections corresponding to the MRI scans are shown. T101 
tumours were stained with an anti-human EGFR antibody. (e) Two representative series of 
coronal sections of T101 brain xenografts, were stained for human EGFR. Mice were treated 
with Erwinase as in (c). (f) Volumes of T101 orthotopic tumours obtained thorough 
quantitative imaging of EGFR-stained serial sections of brains. Mice were treated with 
Erwinase as in (c). Mean ± S.E.M. n=7 mice. p value refer to a two-tailed t test for unpaired 
samples. (g) Coronal section of human T407 GBM xenograft grown in brain of 
immunocompromised mice, and stained for human nestin and GS. Left panels are 
magnification of the respective framed regions. A: astrocytes, V: blood vessel. (h) 15N1-Gln 
enrichment in T407 GBM tumours and in contralateral brains, after a 4h intracarotid 
infusion with . The dashed lines correspond to the natural abundance of 15N1-Gln. 
Mean ± S.E.M. n=4 mice. p value refer to a two-tailed t test for paired samples.
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Figure 8. 
Astrocytes feed with Gln GBM cells. (a, b) Astrocytes were incubated in SMEM for 6 days 
with 0, 0.1, 0.3, 0.65, 1, 2, 4mM Gln (a) or for the indicated times with 0 and 0.65mM Gln 
(b). (c) Astrocytes derived from two independent extractions, and cell lines, were incubated 
for 3 days +/− Gln and protein expression assessed. Unprocessed scans of western blots are 
shown in Supplementary Figure 8. (d-j) Astrocytes were incubated in SMEM for 24h in the 
presence of 5.56mM Glucose (13C6 or 13C0), 0.65mM Gln (13C5 or 13C0), 0.8mM 15NH4+, 
and 1mM MSO as indicated. Secretion/consumption rates (positive/negative bars 
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respectively) are shown for Gln (d) and Glu (e). Intracellular levels of Gln (f) and Glu (g) 
isotopologues are reported as % of control (total of isotopologues in Gln fed conditions). 
The intracellular isotopologues of Gln (h), Glu (i), AMP (j) are shown as % of control (total 
isotopologues in the presence of Gln and 15NH4. (k) Astrocytes were incubated for 6 days +/
− 0.65mM Gln, and 1mM MSO and counted. (l) Astrocytes were grown to confluence in 
multi-well plates. iRFP4 cells were seeded in wells +/− astrocytes, and +/− Gln. The 
fluorescence of iRFP4 cells in representative wells is shown. The experiment was performed 
twice with comparable results. (m) Astrocytes were grown to confluence in multi-well 
plates. iRFP4 cells seeded in transwell inserts were co-cultured +/− astrocytes, +/−Gln, and 
+/− Erwinase (Erw) as indicated. Fluorescence of iRFP4 cells in representative inserts is 
shown. At day 5 astrocytes were stained with sulphorodamine-B and the fluorescence of 
representative wells is shown. (n) Quantification of the iRFP4 fluorescence as described for 
(m). (a, b, d, e, f, g, h, i, j, k, n) Data derive from one experiment performed twice. Raw 
data of independent repeats are provided in the statistics source data Supplementary Table 5.
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